GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhenomeX Inc (NAS:CELL) » Definitions » Cash-to-Debt

PhenomeX (PhenomeX) Cash-to-Debt : 1.07 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is PhenomeX Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PhenomeX's cash to debt ratio for the quarter that ended in Jun. 2023 was 1.07.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PhenomeX could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for PhenomeX's Cash-to-Debt or its related term are showing as below:

CELL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.52   Med: 3.4   Max: 7.05
Current: 1.07

During the past 5 years, PhenomeX's highest Cash to Debt Ratio was 7.05. The lowest was 0.52. And the median was 3.40.

CELL's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.46 vs CELL: 1.07

PhenomeX Cash-to-Debt Historical Data

The historical data trend for PhenomeX's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PhenomeX Cash-to-Debt Chart

PhenomeX Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
5.04 2.83 6.19 3.79 2.90

PhenomeX Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.24 2.89 2.90 0.52 1.07

Competitive Comparison of PhenomeX's Cash-to-Debt

For the Biotechnology subindustry, PhenomeX's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhenomeX's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhenomeX's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PhenomeX's Cash-to-Debt falls into.



PhenomeX Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PhenomeX's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

PhenomeX's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhenomeX  (NAS:CELL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


PhenomeX Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PhenomeX's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


PhenomeX (PhenomeX) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 320, Emeryville, CA, USA, 94608
PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
Executives
Siddhartha Kadia director, officer: Chief Executive Officer 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Mehul Joshi officer: Chief Financial Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Peter Silvester director C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
John R Chiminski director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bird Mergersub Corp 10 percent owner 40 MANNING ROAD, BILLERICA MA 01821
Bruker Corp 10 percent owner 40 MANNING RD, BILLERICA MA 01821
James Paul Mcclaskey officer: SVP, Chief Accounting Officer C/O BERKELEY LIGHTS, INC., C/O BERKELEY LIGHTS, INC., EMERYVILLE CA 94608
Scott David Chaplin officer: Chief Legal Officer 3101 WILSON BOULEVARD, SUITE 700, ARLINGTON VA 22201
Eric Hobbs director, officer: Chief Executive Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
James Rothman director 135 EAST 83RD STREET, APT. 15C, NEW YORK NY 10028
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Keith Breinlinger officer: Chief Technical Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Igor Y Khandros director, 10 percent owner 25 HACIENDAS ROAD, ORINDA CA 94563
Stuart L Merkadeau officer: General Counsel 7005 SOUTHFRONT ROAD, LIVERMORE CA 94551